Sonnet BioTherapeuticsSONN
Market Cap: $5.41M
About: Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Employees: 12
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
367% more capital invested
Capital invested by funds: $118K [Q1] → $550K (+$432K) [Q2]
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
16.79% more ownership
Funds ownership: 2.06% [Q1] → 18.85% (+16.79%) [Q2]
10% more funds holding
Funds holding: 10 [Q1] → 11 (+1) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Chardan Capital Keay Nakae 0 / 0 met price target | 2,785%upside $30 | Buy Maintained | 23 Aug 2024 |
Financial journalist opinion
Based on 3 articles about SONN published over the past 30 days